Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Lazabemide hydrochlorideCat. No. 2460 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Alternative Name: Ro 19-6327 Chemical Name: N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrochloride |
Biological Activity
Selective, reversible monoamine oxidase B (MAO-B) inhibitor (IC50 values are 0.03 and > 100 μM for MAO-B and MAO-A respectively). Inhibits monoamine uptake at high concentrations (IC50 values are 86, 123 and > 500 μM for noradrenalin, serotonin and dopamine uptake respectively).Certificate of Analysis / Safety Data Sheet
References
Saura et al (1992) Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J.Neurosci. 12 1977. PMID: 1578281.
Bondiolotti et al (1995) In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl. Biochem.Pharmacol. 50 97. PMID: 7605351.
Guimaraes and Soares-da-Silva (1998) The activity of MAO A and B in rat renal cells and tubules. Life Sci. 62 727. PMID: 9489509.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Lazabemide hydrochloride, supplier, Selective, MAO-B, inhibitors, Monoamine, Oxygenases, Oxidases, Ro196327
Quick Order
Find multiple products by catalog number
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
New Products in this Area
Cyclooxygenase-inhibiting nitric oxide donor
Tocris Events
Meet your representative
The Role of Cytokines and Signaling in Inflammation
October 15, 2013
Bonn, Germany